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Decay-accelerating  factor  (DAF)  is  an  intrinsic  membrane  glycoprotein  of 
70,000  moi wt  that  inhibits  complement-mediated cell lysis (1-3).  Recent evi- 
dence suggests that it inhibits the assembly of the C3 and C5 convertases of both 
the classical and alternative pathways (3-5). DAF was first described in erythro- 
cytes, but more recently has been demonstrated in other blood cells including 
lymphocytes, monocytes, granulocytes, and platelets (6-8). A deficiency of DAF 
has  been associated  with  paroxysmal nocturnal  hemoglobinuria (PNH),  an ac- 
quired hemolytic disorder (4, 9,  10). The defect leads to an enhanced suscepti- 
bility of the red cells to lysis by complement (11).  In this study, we present the 
first evidence that  DAF  is present in and synthesized by human umbilical vein 
endothelial cells (HUVEC). 
Materials and Methods 
Endothelial Cells.  HUVEC were obtained and maintained in culture for from one to 
three passages in medium 199 containing 20% human serum, 20 t~g/mi crude endothelial 
cell growth factor, and 90 ~g/ml heparin (12-15). 
Preparation of Cell Extracts.  Confluent HUVEC were solubilized by one of two meth- 
ods. Cell extracts for immunoradiometric assay and for Western blotting were prepared 
from confluent cell layers. The cells  were detached from culture flasks  with a  rubber 
policeman and solubilized (107 cells/ml) with 0.5% NP-40 in PBS containing 25 ~g/ml of 
the synthetic elastase  inhibitor Suc(OMe)-ala-ala-pro-val-MCA (Peninsula Laboratories, 
Inc.,  Belmont, CA),  0.5  mM  PMSF (Sigma Chemical Co.,  St.  Louis,  MO),  2.5 t~g]ml 
soybean trypsin inhibitor (Sigma Chemical Co.), and 50 U/ml Trasyloi (Mobay Chemical 
Corp., Pittsburgh, PA). The mixture was incubated for 20 rain on ice and centrifuged at 
12,000 g for 15 min at 4°C to remove insoluble materials. Cell extracts for immunoiso- 
lation of radiolabeled DAF from [3SS]methionine-labeled cell cultures were prepared by 
solubilizing confluent endothelial cell layers with 2% SDS as described previously (16). 
mAb Against DAF.  Three mAb with specificity for purified human DAF were used for 
these studies: IA10 (IgG2a), IIH6, and VIIIA7 (IgG1). The production and specificity of 
these antibodies are described elsewhere (8). 
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lmmunofluorescence  Studies.  First passage HUVEC were grown to confluence in micro- 
titer wells in  medium  199 containing 20%  FCS.  The wells were gently washed several 
times with serum-free medium. The cell monolayers were incubated for 1 h at 37°C with 
either a mixture of anti-DAF mAb or normal mouse IgG at a final  concentration of 10 
tzg/ml each in PBS, washed three times with PBS, and then incubated with fluoresceinated 
goat anti-mouse IgG antibody (Cappel  Laboratories, Cochranville, PA). The monolayers 
were again washed three times with PBS and examined with a Leitz fluorescence micro- 
scope. 
FACS Analysis.  ~ 107 first passage H UVEC obtained by scraping the bottom of culture 
flasks with a  rubber policeman were resuspended in  PBS, pH 7.4 containing 1%  BSA, 
0.1% sodium azide, and 5 mM EDTA. After washing,  the cells were divided into aliquots 
and incubated with a mixture of mAb against DAF (5 12g/ml each) for 30 min on ice. The 
cells were washed three times with the same PBS and incubated with a  fluoresceinated 
goat F(ab')~ anti-mouse IgG (H and L chain-specific) (Cappel  Laboratories) for 30 rain 
on ice.  After washing three times with the same PBS,  the cells  were analyzed by flow 
cytometry. Controls included normal peripheral blood cells stained with  the mixture of 
anti-DAF mAb, as well as cells incubated with  irrelevant mAb of the same subclasses as 
the primary antibody. 
Two-site Immunoradiometric  Analysis of Endothelial  Cells.  This  was performed as  de- 
scribed  previously (8). In  brief,  anti-DAF  monoclonal IA10 was  used  as  a  capturing 
antibody to coat wells of plastic plates.  Cell extracts or serial dilutions of pure DAF were 
added to the wells. After incubation and washing, bound DAF was detected by ~25I-labeled 
anti-DAF monoclonal IIH6, which recognizes a different epitope from IA 10. The amounts 
of DAF in the cell extracts were calculated from a standard curve obtained with purified 
DAF. This standard curve, in which counts bound of the revealing antibody were plotted 
as  a  function  of DAF concentration,  was  linear  up  to  250  ng DAF/ml.  The  protein 
concentration was measured by the method of Lowry et al. (17) using BSA as a reference 
protein. 
Western Blotting of  Endothelial Cell Extract.  Protein A-Sepharose (100 121) was incubated 
with  5 ml of culture supernatant containing mAb IA10 for  1 h  at room temperature. 
IA10-protein A-Sepharose was washed twice with PBS and then incubated with NP-40 
extracts of H UVEC (20 t21 beads per 1 ml of the extract) for 1 h at 4 oc. The bound DAF 
molecules were eluted from the beads by incubation for 5  rain at 80°C with  50 121 of 
sample  buffer consisting of 5%  SDS/125  mM  Tris  HCI, pH  6.8/10%  glycerol/0.01% 
bromphenol blue.  The eluates  were subjected to SDS-PAGE (16)  using 7.5%  gels  and 
transferred electrophoretically to nitrocellulose paper (18-20). DAF was detected on the 
nitrocellulose paper using ~25I-labeled IA10 followed by autoradiography. 
Biosynthetic Labeling of DAF with [sSS]Methionine.  [35S]methionine-labeled  DAF was 
isolated from HUVEC radiolabeled with  [3~S]methionine  (100 12Ci/mi for 20 h) with a 
mixture of anti-DAF mAb, as described previously for the isolation  of thrombospondin 
from HUVEC (16).  The immunoisolated proteins were analyzed by SDS-PAGE with a 
4%  stacking gel and  7.5%  separation gel (19),  followed by autoradiography of the gel 
after treatment with an autoradiography enhancer (ENnHANCE; New England Nuclear, 
Boston, MA). Molecular weights were estimated using ~4C-labeled marker proteins (New 
England Nuclear): phosphorylase (94,000), BSA (67,000), arid ovalbumin (45,000). 
Results and Discussion 
The initial  studies  to determine  whether DAF was present on the surface of 
endothelial  cells were performed using indirect  immunofluorescence and  light 
microscopy.  Live  confluent  monolayers  of  HUVEC  were  incubated  with  a 
mixture of all three anti-DAF mAb, washed, and incubated with fluoresceinated 
goat anti-mouse IgG. Surface fluorescence was visible on all cells in the mono- 
layer.  Control studies  using normal mouse IgG as a  primary antibody followed 
by the fluorescent second antibody were negative (data not shown). ASCH ET  AL.  BRIEF  DEFINITIVE REPORT  223 
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FIGURE  1.  Flow  cytometry.  Solid lines represent fluorescence  observed with anti-DAF mon- 
oclonals. Dotted lines  show nonspecific  fluorescence  observed with  irrelevant  mAb of  the same 
subclass. 
When  analyzed by  flow  cytometry (FACS),  the  endothelial cells  displayed 
surface fluorescence intensity that was approximately four times that of periph- 
eral blood monocytes and seven times that of neutrophils (Fig. 1). Control FACS 
studies  on  endothelial cells  stained  with  irrelevant  monoclonals of the  same 
subclasses were negative. 
To quantitate the number of DAF molecules per  cell, a  known number of 
endothelial cells were solubilized with NP-40  and the amount of DAF in the 
extract determined by double antibody RIA. An average of 3.3 ×  10 ~ molecules 
of DAF were present on each endothelial cell, a  much higher value than that 
obtained for blood cells (11). 
By Western blotting, endothelial cell DAF comigrated with purified erythro- 
cyte  DAF  (Fig.  2).  Western  blots  of the  same  samples  performed  with  an 
irrelevant monoclonal of the same subclasses were negative (data not shown). To 
demonstrate that the DAF present in endothelial cells was synthesized by the 
cells,  nearly confluent HUVEC were labeled for 20 h  with [3~S]methionine and 
solubilized, and ~SS-labeled  DAF was immunoisolated using a  mixture of anti- 
DAF mAb. SDS-PAGE and autoradiography of the immunoisolate demonstrated 
the presence of immunoreactive DAF of mol wt 70,000 synthesized by cultured 
human endothelial cells (Fig.  3),  showing de  nova synthesis of DAF.  Normal 
mouse IgG failed to immunoprecipitate any radioactivity. 
Like peripheral blood cells,  endothelial cells are continuously exposed to the 
plasma  milieu and are  susceptible to complement-mediated cell damage.  Our 
own data demonstrates the presence and synthesis of DAF by HUVEC. This is 
the first evidence for the presence of DAF in cells of extra-marrow origin. DAF 
may have a  role in protecting the endothelial cell from complement-mediated 
damage. Deficiency or disorders of DAF function may result in endothelial cell 
injury and may thus play an important role in a variety of pathologic conditions. 
Exposed subendothelium may lead  to platelet deposition with subsequent de- 
granulation and release of thrombogenic materials. In addition, platelet-derived 
growth factor released under these circumstances may lead to smooth muscle 
cell proliferation. Alternatively, under some conditions, the accelerated deposi- 
tion of activated complement products on the endothelial cell surface may result 
in the recruitment of inflammatory cells and vasculitis. 224  ASCH  ET  AL.  BRIEF  DEFINITIVE  REPORT 
FIGURE 2.  Western blotting. Immunoisolates of DAF from endothelial cell extracts or red 
cell stroma were subjected to SDS-PAGE.  The proteins were electrophoretically transferred 
to nitrocellulose paper and probed with 1251-labeled monoclonal IA10. (1) DAF from red cell 
stroma. (2) DAF immunoisolated from endothelial cell extracts. 
FIGURE 3.  Biosynthetic labeling of DAF  with  [sSS]methionine. Nearly  confluent  HUVEC 
were labeled for 20 h with [3SS]methionine (100/*Ci/ml). DAF immunoisolates were subjected 
to SDS-PAGE and autoradiography was performed. (1) A control immunoisolate using normal 
mouse  IgG  showing an  absence of radioactivity.  (2)  Immunoprecipitated  material isolated 
using anti-DAF  mAb.  A  broad band is  shown by the arrow,  corresponding to M,  68,000. 
Lower molecular weight material may represent proteolyzed DAF. 
Summary 
Decay-accelerating  factor (DAF) has been previously described only in cells of 
bone  marrow  origin  where  it  serves  as  a  negative  modulator  of complement 
activation.  Using  mAb against human  DAF,  we demonstrated  the presence  of ASCH ET  AL.  BRIEF  DEFINITIVE  REPORT  225 
DAF in human umbilical vein endothelial cells by immunofluorescence micros- 
copy and flow cytometry. By means of an immunoradiometric assay we detected 
an average of 3.3  ×  l0 p molecules of DAF on each cell. When immunoisolates 
were  analyzed  in  Western  blots,  endothelial  cell  DAF  comigrated  with  DAF 
purified from normal erythrocytes. DAF was synthesized by the endothelial cells 
since  SsS-labeled  DAF  could  be  immunoisolated  from  HUVEC  cultured  in 
medium containing [S~S]methionine. This is the first evidence for the presence 
of DAF in cells of extra-marrow origin. DAF may protect endothelial cells from 
complement-mediated injury. 
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